MiMedx Group Inc (MDXG)

NASDAQ
Currency in USD
6.66
-0.12(-1.77%)
Closed·
After Hours
6.660.00(0.00%)
·
MDXG Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MDXG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.576.79
52 wk Range
5.4710.14
Key Statistics
Edit
Prev. Close
6.78
Open
6.76
Day's Range
6.57-6.79
52 wk Range
5.47-10.14
Volume
630.64K
Average Volume (3m)
712.53K
1-Year Change
-1.02%
Book Value / Share
1.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDXG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.00
Upside
+80.18%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

MiMedx Group Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

MiMedx Group Inc Company Profile

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company’s wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company’s products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

MiMedx Group Inc SWOT Analysis


Market Dynamics
Explore MIMEDX's position in the $3.9 billion Advanced Wound Care and Surgical Markets, with projected growth in skin substitutes segment to $2.0 billion by 2026
Financial Resilience
Delve into MIMEDX's robust financial health, with 83.4% gross margin and 10.9% revenue growth, despite market challenges and regulatory headwinds
Clinical Excellence
Learn about MIMEDX's product differentiation, supported by over 50 publications showcasing strong clinical results, including a 97% wound closure rate for DFUs
Strategic Outlook
Discover MIMEDX's strategic initiatives, including new product launches and market expansion, with analyst targets around $11.00 per share
Read full SWOT analysis

MiMedx Group Inc Earnings Call Summary for Q1/2025

  • MiMedx Q1 2025: EPS $0.06, revenue $88.2M (+4% YoY). Surgical sales +16%, wound sales -2%. Stock down 2.33% aftermarket.
  • Adjusted gross profit margin 84%, EBITDA $17M (20% of net sales). Cash balance up $2M to $106M.
  • Full-year outlook: High single-digit revenue growth, adjusted EBITDA margin >20%. Aims for low double-digit growth post-reform.
  • CEO emphasizes advocacy for market reform. Company faces ongoing Medicare reimbursement challenges.
  • Analysts set price targets $12-$15. InvestingPro: Stock undervalued, financial health score 3.61/5 ('GREAT').
Last Updated: 2025-04-30, 05:28 p/m
Read Full Transcript

Compare MDXG to Peers and Sector

Metrics to compare
MDXG
Peers
Sector
Relationship
P/E Ratio
24.6x−5.3x−0.5x
PEG Ratio
−0.650.000.00
Price/Book
4.9x1.8x2.6x
Price / LTM Sales
2.8x9.3x3.1x
Upside (Analyst Target)
77.0%209.8%46.1%
Fair Value Upside
Unlock32.9%6.9%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.00
(+80.18% Upside)

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
0.06 / 0.06
Revenue / Forecast
88.20M / 86.36M
EPS Revisions
Last 90 days

MDXG Income Statement

People Also Watch

148.17
KRYS
-1.05%
24.36
ACHC
-1.34%
17.10
TGNA
-1.89%
61.70
NXT
-1.47%
31.45
RNA
-0.06%

FAQ

What Is the MiMedx (MDXG) Stock Price Today?

The MiMedx stock price today is 6.66

What Stock Exchange Does MiMedx Trade On?

MiMedx is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for MiMedx?

The stock symbol for MiMedx is "MDXG."

What Is the MiMedx Market Cap?

As of today, MiMedx market cap is 983.70M.

What Is MiMedx's Earnings Per Share (TTM)?

The MiMedx EPS (TTM) is 0.27.

When Is the Next MiMedx Earnings Date?

MiMedx will release its next earnings report on Aug 05, 2025.

From a Technical Analysis Perspective, Is MDXG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has MiMedx Stock Split?

MiMedx has split 0 times.

How Many Employees Does MiMedx Have?

MiMedx has 837 employees.

What is the current trading status of MiMedx (MDXG)?

As of Jul 12, 2025, MiMedx (MDXG) is trading at a price of 6.66, with a previous close of 6.78. The stock has fluctuated within a day range of 6.57 to 6.79, while its 52-week range spans from 5.47 to 10.14.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.